The Penn State Research Foundation

Gavin P Robertson

Shantu G Amin

Dhimant H Desai

Arati K Sharma

Chandagalu D Raghavendra Gowda

Omer F Kuzu

Arun K Sharma

Gajanan S Inamdar

Subbarao V Madhunapantula

Raghavendra Gowda Chandagalu D

SubbRao V Madhunapantula

Gregory Kardos

Chandagalu D Raghavendragowda

Sanjay Singh

SubbaRao V Madhunapantula

The present invention relates to compositions and methods for treatment of proliferative disease. In specific aspects, the present invention relates to compositions including celecoxib and plumbagin in combination; methods for treatment of a proliferative disease including administration of celecoxib and plumbagin in a subject in need thereof; and particularly methods for treatment of skin cancer including administration of celecoxib and plumbagin in a subject in need thereof.

Compositions and methods including celecoxib and plumbagin relating to treatment of cancer

The present invention relates to compositions and methods for treatment of proliferative disease. In specific aspects, the present invention relates to compositions including (1R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-1-,4a-dimethyl-7-(1-methylethyl)-1-phenanthrenemethanamine (leelamine) and arachidonyl trifluoromethyl ketone (ATK) in combination; methods for treatment of cancer including administration of leelamine and ATK in a subject in need thereof; and particularly methods for treatment of skin cancer including administration of leelamine and ATK in a subject in need thereof.

Compositions and methods including leelamine and arachidonyl trifluoromethyl ketone relating to treatment of cancer

Compositions and pharmaceutical compositions including one or more selenium-containing COX-2 inhibitors are provided according to aspects of the present invention. Methods of treating a subject having or suspected of having cancer are provided according to aspects of the present invention which include administering a therapeutically effective amount of a pharmaceutical composition including a selenium-containing COX-2 inhibitor.

Anti-cancer compositions and methods

Anti-cancer compositions and methods are described herein. In particular, compositions including one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described. Methods for treatment of pathological conditions particularly cancer, in a subject using one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described herein.

Compositions and methods relating to proliferative diseases

Anti-cancer compositions and methods are described including one or more isothiocyanates and/or isoselenocyanates. Methods of treating a subject are provided according to embodiments of the present invention which include administering a therapeutically effective amount of a composition including an isothiocyanate and/or isoselenocyanate to a subject having a condition characterized by Akt dysregulation. Administering a therapeutically effective amount of a composition including an isothiocyanate and/or isoselenocyanate to a subject detectably increases apoptosis and/or decreases proliferation of cancer cells, particularly cancer cells characterized by Akt dysregulation.

Anti-cancer compositions and methods are described including one or more compounds having the structural formula I: R2-R&#x2014;R1, where R is phenyl, where R1 is (CH)&#x2014;Se&#x2014;C(&#x2550;NH)&#x2014;NH, where R2 is (CH)&#x2014;Se&#x2014;C(&#x2550;NH)&#x2014;NHor R2 is H, and where each n is independently 2, 3, 4, 5, 6, 7, or 8. Methods of treating a subject are provided according to embodiments of the present invention which include administering a therapeutically effective amount of a composition including one or more compounds having the structural formula I to a subject having a condition characterized by Akt dysregulation. Administering a therapeutically effective amount of a composition including one or more compounds having the structural formula I to a subject detectably increases apoptosis and/or decreases proliferation of cancer cells, particularly cancer cells characterized by Akt dysregulation. Compositions of the present invention inhibit Akt enzymes, iNOS, and increase MAP kinase activity such that cancer cells contacted with the compositions are inhibited.

Anti-cancer compositions and methods are described including one or more compounds having the structural formula I: R2-R-R1, where R is phenyl, where R1 is (CH)Se&#x2014;C(&#x2550;NH)&#x2014;NH, where R2 is (CH)Se&#x2014;C(&#x2550;NH)&#x2014;NHor R2 is H, and where each n is independently 2, 3, 4, 5, 6, 7, or 8. Methods of treating a subject are provided according to embodiments of the present invention which include administering a therapeutically effective amount of a composition including one or more compounds having the structural formula I to a subject having a condition characterized by Akt dysregulation. Administering a therapeutically effective amount of a composition including one or more compounds having the structural formula I to a subject detectably increases apoptosis and/or decreases proliferation of cancer cells, particularly cancer cells characterized by Akt dysregulation. Compositions of the present invention inhibit Akt enzymes, iNOS, and increase MAP kinase activity such that cancer cells contacted with the compositions are inhibited.

Anti-cancer compositions and methods are described including one or more compounds having the structural formula I: where R is phenyl, where R1 is (CH)&#x2014;Se&#x2014;C(&#x2550;NH)&#x2014;NH, where R2 is (CH)&#x2014;Se&#x2014;C(&#x2550;NH)&#x2014;NHor R2 is H, and where each n is independently 2, 3, 4, 5, 6, 7, or 8. Methods of treating a subject are provided according to embodiments of the present invention which include administering a therapeutically effective amount of a composition including one or more compounds having the structural formula I to a subject having a condition characterized by Akt dysregulation. Administering a therapeutically effective amount of a composition including one or more compounds having the structural formula I to a subject detectably increases apoptosis and/or decreases proliferation of cancer cells, particularly cancer cells characterized by Akt dysregulation. Compositions of the present invention inhibit Akt enzymes, iNOS, and increase MAP kinase activity such that cancer cells contacted with the compositions are inhibited.

Growing community of inventors

Hummelstown, PA, United States of America

Gavin P Robertson